For patients newly diagnosed with small cell lung cancer (SCLC), the conversation about clinical trials should begin immediately, according to a new awareness effort from the Lung Cancer Foundation of America (LCFA). The organization is urging patients to ask their doctors early: “Is there a clinical trial that might be right for me?”
Many patients associate clinical trials with a last resort after standard treatments fail. However, Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, explains that this is not always the case. “Some clinical trials are available only before treatment begins, while others are studying promising therapies as a first treatment,” Saxena said. For a fast-moving cancer like SCLC, timing is critical.
The treatment landscape for SCLC is rapidly evolving. “There are a lot of changes going on in the landscape today, more than we've seen for a very long time,” Saxena noted. Emerging approaches include immunotherapy, which harnesses the immune system to attack cancer cells, and antibody-drug conjugates, which deliver chemotherapy directly to cancer cells while sparing healthy tissue. Researchers are also learning more about the biology of SCLC, potentially leading to more personalized treatments.
These advances offer new hope for patients. For years, treatment options were limited, but clinical trials are expanding what is possible. “All of these things should give patients a lot of hope when they are diagnosed with small cell lung cancer,” Saxena added.
Beyond extending life, clinical trials are increasingly focused on improving how patients feel. Researchers now track patient-reported outcomes such as fatigue, breathing problems, pain, and emotional well-being. “The goal is to have meaningful time, not just more time,” Saxena emphasized. These outcomes can also provide early clues about treatment effectiveness before scans show changes.
Patients themselves play a vital role in their care. Reporting side effects and changes in symptoms can help doctors adjust medications and manage symptoms, potentially allowing patients to stay on treatment longer. In trials, this feedback helps researchers understand the therapy's impact on daily life.
Wendy Brooks, who is living with SCLC and is a member of LCFA's Voices of Hope Speakers Bureau, is encouraged by the pace of change. “I'm more hopeful today than I have ever been,” Brooks said.
The message from LCFA is clear: ask about clinical trials early, before treatment begins, and keep asking throughout the treatment journey. That single question could open doors to new possibilities. To learn more, visit LCFAmerica.org.
